IOL Chemicals & Pharmaceuticals Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/j8g54q9q4kh8ov7ciprcmtru.pdf

Key Takeaways


Chemicals Segment: The Inventory Overhang

Dr. Sanjay Chaturvedi: "Believe me, if acetic acid was available domestically through manufacturers in India, none of the ethyl acetate manufacturers would be facing this issue."

Pharmaceuticals Segment: Building the Quality Mix

Dr. Sanjay Chaturvedi: "I would say in the next 2 years, one should expect that the non-ibuprofen portfolio will exceed the revenues from the ibuprofen portfolio."

Capacity Expansion & Capex

Dr. Sanjay Chaturvedi: "This is actually a year I would argue that we spent more on Capex than any other year. And in fact, a lot of the Capex spend that we have done has gone into things like EHS to take care of the environment, and into warehousing. These are investments into Capex that don't necessarily translate directly into revenue. But to me, they are as strong of an indicator as a buyback program."

Regulatory & Market Access Progress


Segment Economics & Margin Structure

Dr. Sanjay Chaturvedi: "I think it is good to understand what the baseline is, and I would say that running an API business at about 15% EBITDA margin is a reasonably good quality business and we will get there by the end of this year."

Guidance & Commitments

CommitmentSpecificsTimeline
Double-digit EBITDA marginsCompany-wide return to double-digit EBITDANext 2 quarters
API EBITDA marginReach ~15% EBITDA marginBy end of this fiscal year
FY23 revenue growthMuted, single-digit growthCurrent fiscal year
FY24 revenue growthDouble-digit top line growth (value, not just volume)Next financial year
Capacity expansion onlineNew specialty chemicals and pharma capacities operationalBy end of this financial year
Chemicals top line growth~20% higher top line from chemicals segmentNext financial year
Ibuprofen utilizationTake asset utilization to ~85%Next few quarters
Non-ibuprofen portfolioExceed ibuprofen revenuesWithin 2 years
Regulatory filingsSteady state of 5–6 product filings per yearOngoing from current elevated rate
Ethyl acetate capacity absorption70–80% of expanded capacity absorbed domesticallyOnce expansion is online

Key Metrics

MetricQ2 FY23
Revenue growth guidanceSingle-digit growth for FY23; double-digit growth expected for next financial year
EBITDA marginBelow double-digit; management expects return to double-digit margins in next 2 quarters
API business EBITDA marginDouble-digit in Q2; target of about 15% by end of FY23
Chemicals business EBITDA margin6% to 8% sustainable range on average
PAT decline55% down (per an analyst's math, stated by an investor, not confirmed by management)
Pharma segment revenue₹250–300 crore per quarter range over last 3–4 years
Non-ibuprofen portfolio revenue~₹500 crore in FY23; expected to exceed ibuprofen revenues in next 2 years
Non-ibuprofen business H1 revenue₹240 crore
Non-ibuprofen asset utilization~50% plus/minus; some plants at 70%, some below 50%
Ibuprofen capacity utilization75% to 80%; target of about 85% in next few quarters
Ibuprofen monthly run rate~800 tonnes per month, roughly 80% of capacity
Ibuprofen export price$11 to $12 per kg; slightly lower for Indian market, pricing stable
Ibuprofen global market share~33% of world capacity; upwards of 50% including intermediates supplied to other manufacturers
Metformin asset utilizationAbove 90%
Metformin export share~10% of volume; rest domestic
Ethyl acetate price change~14% decline Q1 to Q2
Acetic acid price change~40% decline Q1 to Q2; roughly 40% YoY
Ethyl acetate exports~20% of production
Ethyl acetate capacity expansion20,000 tonnes per year; expected online by end of FY23, accruals from Q1 FY24
Capex guidance₹100–150 crore per annum
Total import dependence~40% of total consumption; chemicals side ~70%, pharma side 15–20% excluding DCDA
Intersegment transfers~₹115 crore in H1 FY23; expected ~₹150 crore plus/minus per year